CORRESPONDENCE

Psychotropic medication: resistance, adherence and religious objections

Mitchell & Selmes (2007) neglect a key reference that is useful in developing our understanding of this issue. Pound et al (2005) conducted the qualitative equivalent of a meta-analysis of issues surrounding the way in which patients take (or don’t take) their medication as prescribed. Out of this was identified the concept of ‘resistance’ to taking medication. This is a significant conceptual and practical theme. It has particular importance as it links the issue of taking psychotropic medication with taking medication in general. Resistance emphasises how taking medication interacts with a patient’s sense of self and how not taking medication needs to be understood in this context.


Daniel M. Beales  Specialist Registrar in Forensic Psychotherapy, Edenfield Centre, Bolton, Salford & Trafford Mental Health NHS Trust, UK (email Daniel.Beales@bstmhft.nhs.uk)
doi: 10.1192/apt.14.1.78

I am responsible for the care of patients on a psychiatric intensive care unit. All of our patients are detained under the Mental Health Act and many do not have capacity to consent to treatment. In my experience the most common causes for relapse are a combination of non-adherence or partial adherence to medication regimens and substance misuse.

‘Compliance therapy’ is a combination of cognitive–behavioural techniques, motivational interviewing techniques and psychoeducation, and it aims to promote a good therapeutic alliance between doctor and patient, with open discussion about the risks and benefits of medication. The therapy has been used with success in patients with psychosis and it reduces readmission rates and improves insight and adherence to medication (Kemp et al, 1996, 1998).

Relapse prevention is as important as treating the acute illness. Non-adherence to medication is an important risk factor that needs close monitoring. It is our responsibility as clinicians to ensure that our patients understand their illness, the need for treatment and the importance of engagement with the services. It is essential that this is in the context of a partnership between doctor and patient.


Marlene M. Kelbrick  Staff Grade Psychiatrist (email: mkelbrick@standrews.co.uk)
doi: 10.1192/apt.14.1.78a

Resolving non-adherence to pharmacotherapy should involve a comprehensive assessment of the patient’s social circumstances and cultural and religious beliefs (Sattar et al, 2004). There is evidence that patients with strong spiritual values cope better with mental illness and have better insight into their condition. Such factors have a direct impact on treatment adherence and engagement in therapy (Kirov et al, 1998).

Religious laws do not restrict the use of psychotropic medications but many forbid the use of animal-based derivatives, specifically gelatinous products and stearic acid. These are generally derived from beef and/or pork products. This has major implications for many patients, particularly the followers of Judaism, Islam, Hinduism, Buddhism, Seventh Day Adventism and the Christian Orthodox Church (Sattar et al, 2004). There are also over four million vegetarians in the UK (Food Standards Agency, 2005).

Initial findings from a postal survey that we conducted locally suggest that many psychiatrists have remained ambivalent about discussing this subject with their patients, for fear of reducing adherence to psychotropic medication, and also that many are unaware of the presence of ‘forbidden contents’ in psychotropic medication.

We believe that, in order to instil a spirit of trust in our patients and improve medication adherence, psychiatrists should have a basic familiarity with religious dietary restrictions. Information on the gelatin or stearic acid content of medications can be obtained from the physicians’ desk reference or electronic databases such as www.PDR.net or www.rxlist.com.

General Medical Council (1998) Seeking Patient’s Consent: The Ethical Considerations. GMC.

doi: 10.1192/apt.14.1.78